APP2022050 Development Grant (McDevitt) 2023 to 2025 National Health and Medical Research Council Breaking drug resistance in community acquired bacterial pneumonia (CABP) The major aim of this project is to develop a combination drug for the treatment of CABP composed of the ionophore PBT2 in combination with the frontline antibiotics amoxicillin and doxycycline. Role: CID.
Awarded date
2023
Degree of recognition
National
Granting Organisations
NHMRC - National Health and Medical Research Council (Australia)